Navigation Links
Ambit Biosciences Announces Third Quarter 2013 Operating Results
Date:11/7/2013

SAN DIEGO, Nov. 7, 2013 /PRNewswire/ -- Ambit Biosciences (NASDAQ: AMBI), a biopharmaceutical company focused on discovery and development of drugs targeting unmet needs in oncology, autoimmune and inflammatory disease, today announced third quarter and year-to-date operating results for 2013.  The company will host a conference call today to discuss financial results for the third quarter and year-to-date, and to provide an operational update on developments in the quarter.

"We are pleased to have made good progress toward our goals during the third quarter, moving forward in the development of our lead drug candidate, quizartinib.  We are excited about the upcoming events at ASH in December, where we will have the opportunity to present data from our most recent studies," said Michael Martino, Ambit's president and Chief Executive Officer. "As we head into the last quarter of 2013, we are looking forward to feedback from our upcoming FDA meeting in November and we will provide an update on our development and regulatory plans for quizartinib following that meeting.  Additionally, we remain on track to start our Phase 3 trial in early-2014, as previously guided."

Operational Update
The Company is pleased to announce the acceptance of four abstracts with preliminary data highlighting the Company's lead drug candidate, quizartinib.  Presentations of the final data and two additional posters will be presented during the ASH 55th Annual Meeting at the Ernest Morial Convention Center in New Orleans, LA on December 9, 2013.  Oral presentations include the following:

Results of Phase 2 Randomized, Open-Label, Study of Lower Doses of Quizartinib in Subjects with FLT3-ITD Positive Relapsed Acute Myeloid Leukemia (AML):  The purpo
'/>"/>

SOURCE Ambit Biosciences
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Ambit Announces Participation At 12th Annual BIO Investor Forum
2. Ambit Announces Participation At The BioCentury NewsMakers in the Biotech Industry Conference
3. Ambit Announces Presentation of Results from Phase 2 ACE Study of Quizartinib in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) at the Annual Meeting of the American Society of Clinical Oncology
4. Ambit Biosciences Files Registration Statement for Proposed Initial Public Offering
5. APAC Stem Cell Research & Therapy Market a “Growth Engine” for Region’s Scientific Ambitions Says A New Market Research Report at ReportsnReports.com
6. Astellas and Ambit Announce Data Presentations Highlighting Quizartinib at the American Society of Hematology 54th Annual Meeting
7. Ambit Biosciences to Present at Two Upcoming Investor Conferences
8. Ambit and Astellas Announce Results From Multiple Quizartinib Presentations at the 53rd Annual Meeting of the American Hematology Society
9. Ambit Biosciences Names Michael A. Martino President and Chief Executive Officer
10. Pressure BioSciences, Inc. Reports Third Quarter 2013 Financial Results and Provides Business Update
11. Juneau Biosciences Names Dr. Dinesh Patel to Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... Aug. 20, 2014 /PRNewswire-iReach/ -- A case study ... between the school,s bioengineering department and the Intel® ... Intel® Software Academic Program, UCSD,s research focuses on ... human body.  Photo - ... the work of Dr. Todd P. Coleman ...
(Date:8/20/2014)... GraphDB™ 6.0 from ... to the enterprise replication cluster, faster loading speeds, ... and Elasticsearch. This release happens to coincide with ... – GraphDB™ was formerly known as OWLIM. ... mature enterprise resilient RDF triplestore will also benefit ...
(Date:8/19/2014)... -- Research and Markets  has announced the addition of the ... report to their offering. This report analyzes ... Thousands by the following Product Segments: Media, Sera, and Reagents. ... Canada , Japan , ... Latin America . Annual estimates and forecasts are provided for ...
(Date:8/19/2014)... 2014 Research and Markets  has announced the ... Global Strategic Business Report" report to their offering. ... Oxide Fuel Cells (SOFCs) in US$ Thousands. The report provides ... , Europe , Asia-Pacific ... provided for the period 2012 through 2020. Market data and ...
Breaking Biology Technology:Intel and University of San Diego Bioengineering Department Release Case Study on Health Sciences Research 2Ontotext Improves Its RDF Triplestore, GraphDB™ 6.0: Enterprise Resilience, Faster Loading Speeds and Connectors to Full-Text Search Engines Top the List of Enhancements 2Ontotext Improves Its RDF Triplestore, GraphDB™ 6.0: Enterprise Resilience, Faster Loading Speeds and Connectors to Full-Text Search Engines Top the List of Enhancements 3Ontotext Improves Its RDF Triplestore, GraphDB™ 6.0: Enterprise Resilience, Faster Loading Speeds and Connectors to Full-Text Search Engines Top the List of Enhancements 4Global Cell and Tissue Culture Supplies - Strategic Business Report 2014 2Global Solid Oxide Fuel Cells (SOFCs) - Strategic Business Report 2014 2
... Microfluidic Systems (MFSI),along with its manufacturing ... invited to attend the U.S. House of,Representatives ... and Responding to Bioterrorism. MFSI will be ... The purpose,of the fair is to educate ...
... Memory,Pharmaceuticals Corp. (Nasdaq: MEMY ) today ... included an explanatory,paragraph in their opinion on the ... Report on Form 10-K for the year ended,December ... continue as a going,concern. The Company discusses this ...
... today,announced it has secured $20 million in venture ... includes Silicon Valley Bank,and Comerica Bank. Aerovance drew ... The remaining $10 million is available upon the ... interest and enthusiasm in Aerovance,and our clinical programs," ...
Cached Biology Technology:Memory Pharmaceuticals Receives Audit Opinion Containing Going Concern Qualification 2
(Date:8/20/2014)... WORCESTER, MA Using population-based screening outcomes of approximately ... states, including four researchers at the University of Massachusetts ... combined immunodeficiency (SCID) can be successfully implemented across public ... programs published in the Aug. 20 issue of the ... JAMA ) showed the rate of SCID in newborns ...
(Date:8/20/2014)... are athletes who have suffered concussions ready to return ... found that high school athletes who head back on ... a significant regression in their abilities to simultaneously walk ... seen in changes in their balance and/or altered walking ... of the 12 had returned to activity in less ...
(Date:8/20/2014)... plastic bags could one day be made out of ... are now reporting. The novel process they developed and ... its agricultural and plastic waste problems, appear in the ... S. Bayer and colleagues at the Italian Institute of ... In 2012, its production reached 288 million tons worldwide, ...
Breaking Biology News(10 mins):Newborn screening expansion offers early diagnosis and treatment to infants with SCID 2Newborn screening expansion offers early diagnosis and treatment to infants with SCID 3Recovery reversal seen in Oregon study of returning concussed athletes 2Recovery reversal seen in Oregon study of returning concussed athletes 3
... be processed unconsciously when the area of the brain ... down, according to research at Rice University in Houston. ... in the Proceedings of the National Academy of Sciences' ... than one pathway along which visual information can be ...
... have identified some of the key factors that prevent ... (MS), complications of premature birth, and other diseases and ... nervous system fails to repair itself and suggest ways ... be reversed. The research is published in the August ...
... an alien if you encountered it on the street tomorrow? ... rather was created in a laboratory right here on Earth ... Peter Ward has the beginnings of an answer. In a ... expanded "tree of life," or biological classification system, to account ...
Cached Biology News:Out of sight, out of mind? Not necessarily 2OHSU researchers discover potential mechanism to repair brain damage linked to Multiple Sclerosis 2OHSU researchers discover potential mechanism to repair brain damage linked to Multiple Sclerosis 3OHSU researchers discover potential mechanism to repair brain damage linked to Multiple Sclerosis 4New book expands biological classifications to account for 'alien' life 2New book expands biological classifications to account for 'alien' life 3
Mouse polyclonal antibody raised against a partial recombinant LASS3. NCBI Entrez Gene ID = 204219...
... Bio-Beads SM-2 adsorbents are macroporous polystyrene ... a high surface area for adsorbing organics ... aqueous solutions. The beads are useful for ... active agents; for example, the removal of ...
MAb to Catenin beta, N-terminal (exon 2) Catenin, beta, N-terminal (exon 2)...
... Phosphate Phosphatase 2 (LPP2) ... aqueous solution Solution ... containing 0.08% sodium azide. ... the human LPP2 protein. ...
Biology Products: